| Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries M Brisson, JJ Kim, K Canfell, M Drolet, G Gingras, EA Burger, D Martin, ... The Lancet 395 (10224), 575-590, 2020 | 616 | 2020 |
| Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries K Canfell, JJ Kim, M Brisson, A Keane, KT Simms, M Caruana, EA Burger, ... The Lancet 395 (10224), 591-603, 2020 | 444 | 2020 |
| Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–99: a modelling study KT Simms, J Steinberg, M Caruana, MA Smith, JB Lew, I Soerjomataram, ... The lancet oncology 20 (3), 394-407, 2019 | 418 | 2019 |
| The projected timeframe until cervical cancer elimination in Australia: a modelling study MT Hall, KT Simms, JB Lew, MA Smith, JML Brotherton, M Saville, ... The Lancet Public Health 4 (1), e19-e27, 2019 | 409 | 2019 |
| Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study KT Simms, SJB Hanley, MA Smith, A Keane, K Canfell The Lancet Public Health 5 (4), e223-e234, 2020 | 179 | 2020 |
| Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National … JB Lew, KT Simms, MA Smith, M Hall, YJ Kang, XM Xu, M Caruana, ... The Lancet Public Health 2 (2), e96-e107, 2017 | 178 | 2017 |
| Projected time to elimination of cervical cancer in the USA: a comparative modelling study EA Burger, MA Smith, J Killen, S Sy, KT Simms, K Canfell, JJ Kim The Lancet Public Health 5 (4), e213-e222, 2020 | 77 | 2020 |
| Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017–2035: example from Australia MT Hall, KT Simms, JB Lew, MA Smith, M Saville, K Canfell PloS one 13 (2), e0185332, 2018 | 77 | 2018 |
| Effectiveness modelling and economic evaluation of primary HPV screening for cervical cancer prevention in New Zealand JB Lew, K Simms, M Smith, H Lewis, H Neal, K Canfell PLoS One 11 (5), e0151619, 2016 | 76 | 2016 |
| Will cervical screening remain cost‐effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries KT Simms, MA Smith, JB Lew, HC Kitchener, PE Castle, K Canfell International journal of cancer 139 (12), 2771-2780, 2016 | 70 | 2016 |
| HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control K Canfell, JJ Kim, S Kulasingam, J Berkhof, R Barnabas, JA Bogaards, ... Papillomavirus Research 8, 100184, 2019 | 52 | 2019 |
| Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling … KT Simms, JF Laprise, MA Smith, JB Lew, M Caruana, M Brisson, ... The Lancet Public Health 1 (2), e66-e75, 2016 | 52 | 2016 |
| Impact of HPV sample self‐collection for underscreened women in the renewed Cervical Screening Program M Smith, JB Lew, K Simms, K Canfell Medical Journal of Australia 204 (5), 194-194, 2016 | 52 | 2016 |
| Estimating the natural history of cervical carcinogenesis using simulation models: a CISNET comparative analysis EA Burger, IMCM De Kok, E Groene, J Killen, K Canfell, S Kulasingam, ... JNCI: Journal of the National Cancer Institute 112 (9), 955-963, 2020 | 46 | 2020 |
| Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates JB Lew, E Feletto, S Wade, M Caruana, YJ Kang, C Nickson, K Simms, ... Public health research & practice 29 (2), 2019 | 41 | 2019 |
| Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use MA Smith, D Gertig, M Hall, K Simms, JB Lew, M Malloy, M Saville, ... BMC health services research 16, 1-14, 2016 | 41 | 2016 |
| Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis JJ Kim, KT Simms, J Killen, MA Smith, EA Burger, S Sy, C Regan, ... PLoS Medicine 18 (3), e1003534, 2021 | 39 | 2021 |
| National Cervical Screening Program Renewal: Effectiveness modelling and economic evaluation in the Australian setting JB Lew, KT Simms, MA Smith, YK Kang, X Xu, M Caruana, R Walker, ... | 37 | 2013 |
| The predicted impact and cost‐effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndrome YJ Kang, J Killen, M Caruana, K Simms, N Taylor, IM Frayling, T Snowsill, ... Medical Journal of Australia 212 (2), 72-81, 2020 | 32 | 2020 |
| Optimal management strategies for primary HPV testing for cervical screening: cost-effectiveness evaluation for the National Cervical Screening Program in Australia KT Simms, M Hall, MA Smith, JB Lew, S Hughes, S Yuill, I Hammond, ... PLoS One 12 (1), e0163509, 2017 | 31 | 2017 |
Karen CanfellCancer Council NSW, University of SydneyVerified email at nswcc.org.au
